FDA’s Accelerated Approval Pathway Drives Momentum for Intractable, Fatal Diseases

Despite hotly debated biomarkers and failed or delayed confirmatory trials, the accelerated approval program has a track record of propelling R&D for some of medicine’s most challenging illnesses.